EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Focal Therapy for Localized Prostate Cancer: A Case Series with Cost Analysis

Maxwell Sandberg iD, David Thole iD, Jackson Nowatzke, Gavin Underwood, Emily Ye, Soroush Rais-Bahrami iD, Ronald Davis, Alejandro Rodriguez

Current Oncology · 2025

DOI: 10.3390/curroncol32090476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Maxwell Sandberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Wake Forest University School of Medicine, Winston Salem, NC 27101, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Cryosurgery. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Focal therapy for prostate cancer (PCa) provides approaches to treat PCa patients in a less invasive manner than traditional whole-gland surgical or radiation modalities. This manuscript provides a case series of high-intensity focused ultrasound (HIFU), cryoablation, and irreversible electroporation (IRE) for PCa at a single institution and cost analysis with a review of the literature. All patients who underwent HIFU, cryoablation, or IRE for localized PCa were retrospectively reviewed, excluding patients who received whole-gland therapy. Functional outcomes were erectile dysfunction and lower urinary tract symptoms. Cost data were collected. A total of 45 patients were included in the study with focal therapy ranging from 2023 to 2025 (4 HIFU, 20 cryoablation, 21 IRE). A total of 30 patients had focally treated lesions, and 15 patients had hemi-gland treatment. The mean preoperative PSA was 7.7 ng/mL. On the paired sample t-test, there was no significant difference between pre-focal and post-focal therapy PSA. Three patients experienced biochemical recurrence requiring prostate biopsy after focal treatment. Mean cost was USD 3804.50 and not significantly different by focal treatment. No metastatic events occurred nor deaths at a median follow-up of 6 months. Patients in this series had largely unaltered functional outcomes. Cost analysis in contemporary publications is lacking. Although follow-up was short, cancer control was adequate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCryosurgeryHumansMaleAgedMiddle AgedCosts and Cost AnalysisRetrospective StudiesHigh-Intensity Focused Ultrasound Ablation

Stichwörter der Autor:innen

HIFUIREcryoablationfocalprostate cancer

Autor:innen und Institutionen

  • Department of Urology, Wake Forest University School of Medicine, Winston Salem, NC 27101, USA.
  • Comprehensive Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston Salem, NC 27101, USA.

ORCID-Profile: Maxwell Sandberg, David Thole, Soroush Rais-Bahrami

Zitieren

APA

Sandberg, M., Thole, D., Nowatzke, J., Underwood, G., Ye, E., Rais-Bahrami, S., Davis, R., & Rodriguez, A. (2025). Focal Therapy for Localized Prostate Cancer: A Case Series with Cost Analysis. Current Oncology. https://doi.org/10.3390/curroncol32090476

Vancouver

Sandberg M, Thole D, Nowatzke J, Underwood G, Ye E, Rais-Bahrami S, et al. Focal Therapy for Localized Prostate Cancer: A Case Series with Cost Analysis. Current Oncology. 2025. doi:10.3390/curroncol32090476

BibTeX
@article{Sandberg2025,
  author = {Sandberg, Maxwell and Thole, David and Nowatzke, Jackson and Underwood, Gavin and Ye, Emily and Rais-Bahrami, Soroush and Davis, Ronald and Rodriguez, Alejandro},
  title = {Focal Therapy for Localized Prostate Cancer: A Case Series with Cost Analysis},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32090476}
}
Kostenlos starten →